You are here: Home » Companies » News
Business Standard

Zydus Cadila gets USFDA nod for anti-inflammatory drug

The company has received final approval to market the drug in the strength of 50 mg/vial.

Press Trust of India  |  New Delhi 

Zydus Cadila swelling reducing drug Ethacrynate sodium gets USFDA nod

has received final approval from the US health regulator to market for injection, used to reduce swelling caused by various diseases.

The company has received final approval from the US Food and Administration (USFDA) to market the in the strength of 50 mg/vial, said in a BSE filing.


The company will produce the at its formulations manufacturing facility in Moraiya,

for injection is used to reduce swelling caused by various diseases including related to liver, kidney, congestive heart failure and cancer.

The company has more than 165 approvals and so far filed over 300 abbreviated new applications (ANDAs) since it commenced filings in 2003-04.

First Published: Sat, November 18 2017. 14:06 IST
RECOMMENDED FOR YOU